Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.